{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:29:18Z","timestamp":1771921758827,"version":"3.50.1"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chronic pain represents a significant global health concern, posing a severe threat to human wellbeing and affecting up to 20% of the adult population. Bulleyaconitine A (BLA), a diterpenoid alkaloid derived from plants of the Aconitum genus with in the Ranunculaceae family, demonstrates remarkable analgesic properties with a low potential for addiction, thus broad clinical application prospects compared to opioids. Extensive research has elucidated multiple pharmacological mechanisms underlying the analgesic effects of BLA, including state-dependent blockade of voltage-gated sodium channels, activation of the \u03ba-opioid receptor pathway in spinal microglia, and anti-inflammatory immunomodulatory effects through inhibition of the NF-\u03baB pathway. These mechanisms have been validated in various pain models, including neuropathic pain, cancer pain, rheumatoid arthritis pain, and visceral pain. However, BLA still faces pharmacokinetic challenges in clinical translation, including a narrow therapeutic window, low bioavailability, and potential neurotoxicity. In recent years, the development of novel drug delivery systems, structural modifications targeting the C-8 and C-14 sites to separate toxicity from efficacy, and advances in artificial intelligence-assisted drug design have provided effective solutions to overcome these limitations. Emerging research suggests that BLA has potential new indications in areas such as visceral hypersensitivity, irritable bowel syndrome, and pain-related anxiety disorders. This article provides a comprehensive review of the ion channel targets, central and peripheral mechanisms of action, pharmacokinetic characteristics, innovative drug delivery strategies, structural optimization pathways, and current clinical application of BLA. It aims to offer valuable references for the further development and rational clinical application of BLA as a non-opioid analgesic with multi-target therapeutic potential.<\/jats:p>","DOI":"10.3389\/fphar.2025.1733973","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:24:38Z","timestamp":1768458278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analgesic effects of bulleyaconitine A: new advances in research from ion channel targets to clinical translation"],"prefix":"10.3389","volume":"16","author":[{"given":"Zili","family":"Yin","sequence":"first","affiliation":[{"name":"Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlian","family":"Song","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changcheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Kunming Medical University Haiyuan College","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anguo","family":"Hou","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e092","DOI":"10.1097\/oi9.0000000000000092","article-title":"The effect of NSAIDs on postfracture bone healing: a meta-analysis of randomized controlled trials","volume":"4","author":"Al Farii","year":"2021","journal-title":"OTA Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Delivery Reviews"},{"key":"B3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0301-0082(98)00037-9","article-title":"The effects of aconitum alkaloids on the central nervous system","volume":"56","author":"Ameri","year":"1998","journal-title":"Prog. Neurobiology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jor.24170","article-title":"Cellular biology of fracture healing","volume":"37","author":"Bahney","year":"2019","journal-title":"J. Orthop. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/s1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1472-8206.2004.00280.x","article-title":"A QSAR analysis of toxicity of aconitum alkaloids","volume":"18","author":"Bello\u2010Ram\u00edrez","year":"2004","journal-title":"Fundam. & Clinical Pharmacology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.neuint.2007.03.002","article-title":"Increased oxidative stress during hyperglycemic cerebral ischemia","volume":"50","author":"B\u00e9meur","year":"2007","journal-title":"Neurochem. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"B9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/00003088-197601030-00004","article-title":"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone","volume":"1","author":"Berkowitz","year":"1976","journal-title":"Clin. Pharmacokinet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00210-003-0815-3","article-title":"Cytochrome P450 3A and their regulation","volume":"369","author":"Burk","year":"2004","journal-title":"Naunyn-Schmiedeberg's Archives Pharmacology"},{"key":"B11","first-page":"1","article-title":"Advance in studies on structure-activity relationships of diterpenoid alkaloids in genus aconitum","volume":"25","author":"Cai","year":"2013","journal-title":"Strait Pharma J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-pharmtox-011112-140232","article-title":"Sodium channels, inherited epilepsy, and antiepileptic drugs","volume":"54","author":"Catterall","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-pharmtox-010818-021757","article-title":"Structure and pharmacology of voltage-gated sodium and calcium channels","volume":"60","author":"Catterall","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/15563650902904407","article-title":"Aconite poisoning","volume":"47","author":"Chan","year":"2009","journal-title":"Clin. Toxicology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/jpr.S53660","article-title":"Neuropathic pain and cytokines: current perspectives","volume":"6","author":"Clark","year":"2013","journal-title":"J. Pain Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/bja\/81.1.58","article-title":"Opioid tolerance: the clinical perspective","volume":"81","author":"Collett","year":"1998","journal-title":"Br. J. Anaesth."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2174\/138161209788186308","article-title":"TRP channels and pain","volume":"15","author":"Cortright","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"B19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pain.2007.07.026","article-title":"The roles of sodium channels in nociception: implications for mechanisms of pain","volume":"131","author":"Cummins","year":"2007","journal-title":"Pain"},{"key":"B20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain - united States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1055\/s-0041-1732334","article-title":"Bone healing and inflammation: principles of fracture and repair","volume":"35","author":"ElHawary","year":"2021","journal-title":"Semin. Plast. Surg."},{"key":"B106","volume-title":"A recycling and utilization method for column chromatography eluent in bulleyaconitine A extraction process. Chinese Patent Application CN 202310624725.7","author":"Fu","year":"2024"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101248","DOI":"10.1016\/j.jpha.2025.101248","article-title":"The future of pharmaceuticals: artificial intelligence in drug discovery and development","volume":"15","author":"Fu","year":"2025","journal-title":"J. Pharm. Analysis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0379-0738(88)90103-x","article-title":"Potentiation of lethality and increase in body temperature by combined use of d-methamphetamine and morphine in mice","volume":"37","author":"Funahashi","year":"1988","journal-title":"Forensic Science International"},{"key":"B25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nri3621","article-title":"Pathological pain and the neuroimmune interface","volume":"14","author":"Grace","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1213\/00000539-199410000-00015","article-title":"Prolonged analgesia and decreased toxicity with liposomal morphine in a mouse model","volume":"79","author":"Grant","year":"1994","journal-title":"Anesth. Analg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jpain.2013.06.008","article-title":"An overview of animal models of pain: disease models and outcome measures","volume":"14","author":"Gregory","year":"2013","journal-title":"J. Pain"},{"key":"B28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-62703-342-8_6","article-title":"On exploring structure-activity relationships","volume":"993","author":"Guha","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2165\/00003088-199324040-00007","article-title":"Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations","volume":"24","author":"Hasselstr\u00f6m","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.gerinurse.2024.04.008","article-title":"The effectiveness, acceptability, and sustainability of non-pharmacological interventions for chronic pain management in older adults in mainland China: a systematic review","volume":"57","author":"He","year":"2024","journal-title":"Geriatr. Nurs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12974-016-0696-2","article-title":"Bullatine A stimulates spinal microglial dynorphin A expression to produce anti-hypersensitivity in a variety of rat pain models","volume":"13","author":"Huang","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jep.2016.12.027","article-title":"Concurrent bullatine A enhances morphine antinociception and inhibits morphine antinociceptive tolerance by indirect activation of spinal \u03ba-opioid receptors","volume":"196","author":"Huang","year":"2017","journal-title":"J. Ethnopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1484087","DOI":"10.1155\/2020\/1484087","article-title":"Bulleyaconitine A inhibits visceral nociception and spinal synaptic plasticity through stimulation of microglial release of dynorphin A","volume":"2020","author":"Huang","year":"","journal-title":"Neural Plast."},{"key":"B35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fphar.2020.00328","article-title":"Bulleyaconitine A exerts antianxiety and antivisceral hypersensitivity effects","volume":"11","author":"Huang","year":"","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/aln.0000000000003651","article-title":"Perineural liposomal bupivacaine is not superior to nonliposomal bupivacaine for peripheral nerve block analgesia","volume":"134","author":"Hussain","year":"2021","journal-title":"Anesthesiology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00210-003-0819-z","article-title":"Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms","volume":"369","author":"Ingelman-Sundberg","year":"2004","journal-title":"Naunyn-Schmiedeberg's Archives Pharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/aln.0000000000002130","article-title":"Neuroinflammation and central sensitization in chronic and widespread pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-8517.2025.12.zgmzmjyyzz202512016","article-title":"The research status of bulleyaconitine A","volume":"34","author":"Jia","year":"2025","journal-title":"Chin. J. Ethnomedicine Ethnopharmacy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"908867","DOI":"10.3389\/fphar.2022.908867","article-title":"Structural advances in voltage-gated sodium channels","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11916-024-01227-5","article-title":"Recent advances in management of neuropathic, nociceptive, and chronic pain: a narrative review with focus on nanomedicine, gene therapy, stem cell therapy, and newer therapeutic options","volume":"28","author":"Kataria","year":"2024","journal-title":"Curr. Pain Headache Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bpa.2020.04.014","article-title":"Chronic pain and substance abuse disorders: preoperative assessment and optimization strategies","volume":"34","author":"Kaye","year":"2020","journal-title":"Best Pract. & Res. Clin. Anaesthesiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fgene.2013.00012","article-title":"Pharmacogenomics of cytochrome P450 3A4: recent progress toward the \u201cMissing Heritability\u201d problem","volume":"4","author":"Klein","year":"2013","journal-title":"Front. Genet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000507","article-title":"Do we need a third mechanistic descriptor for chronic pain states?","volume":"157","author":"Kosek","year":"2016","journal-title":"Pain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/s0169-409x(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Delivery Reviews"},{"key":"B46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.brainres.2010.02.070","article-title":"The kappa-opioid receptor is upregulated in the spinal cord and locus ceruleus but downregulated in the dorsal root ganglia of morphine tolerant rats","volume":"1326","author":"Li","year":"2010","journal-title":"Brain Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fphar.2016.00367","article-title":"Ester hydrolysis differentially reduces aconitine-induced anti-hypersensitivity and acute neurotoxicity: involvement of spinal microglial dynorphin expression and implications for aconitum processing","volume":"7","author":"Li","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"45056","DOI":"10.1038\/srep45056","article-title":"Molecular signaling underlying bulleyaconitine A (BAA)-induced microglial expression of prodynorphin","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"116024","DOI":"10.1016\/j.taap.2022.116024","article-title":"Bulleyaconitine A is a sensitive substrate and competitive inhibitor of CYP3A4: one of the possible explanations for clinical adverse reactions","volume":"445","author":"Li","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1021\/acsanm.4c06849","article-title":"Modulation of macrophage polarization in rheumatoid arthritis therapy via targeted delivery of bulleyaconitine A","volume":"8","author":"Li","year":"2025","journal-title":"ACS Appl. Nano Mater."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3969\/j.issn.1007-8517.2021.20.zgmzmjyyzz202120014","article-title":"The research status of bulleyaconitine","volume":"30","author":"Lin","year":"2021","journal-title":"Chin. J. Ethnomedicine Ethnopharmacy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1534735407305705","article-title":"Chinese herbal medicine for cancer pain","volume":"6","author":"Ling","year":"2007","journal-title":"Integr. Cancer Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1080\/09168451.2020.1752140","article-title":"Bulleyaconitine A inhibits the lung inflammation and airway remodeling through restoring Th1\/Th2 balance in asthmatic model mice","volume":"84","author":"Liu","year":"2020","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/s0896-6273(02)00828-0","article-title":"Function and regulation of CREB family transcription factors in the nervous system","volume":"35","author":"Lonze","year":"2002","journal-title":"Neuron"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1744806920917242","DOI":"10.1177\/1744806920917242","article-title":"Oral application of bulleyaconitine A attenuates morphine tolerance in neuropathic rats by inhibiting long-term potentiation at C-fiber synapses and protein kinase C gamma in spinal dorsal horn","volume":"16","author":"Mai","year":"2020","journal-title":"Mol. Pain"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.35975\/apic.v24i5.1352","article-title":"Revised definition of pain by \u2018international association for the study of pain\u2019: concepts, challenges and compromises","volume":"24","author":"Malik","year":"2020"},{"key":"B58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s0304-3959(02)00422-0","article-title":"Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy","volume":"100","author":"Mao","year":"2002","journal-title":"Pain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1021\/acsnano.1c08284","article-title":"Osteoblast\/osteoclast and immune cocktail therapy of an exosome\/drug delivery multifunctional hydrogel accelerates fracture repair","volume":"16","author":"Mi","year":"2022","journal-title":"ACS Nano"},{"key":"B60","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/npp.2008.110","article-title":"Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition","volume":"34","author":"Miksys","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Reviews Drug Discovery"},{"key":"B62","article-title":"Studies On Aconitum Species. VIII. Heterocycles","volume":"29","author":"Mori","year":"1989"},{"key":"B63","first-page":"1551","article-title":"Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs","volume":"26","author":"Niemegeers","year":"1976","journal-title":"Arzneimittelforschung"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1046514","DOI":"10.3389\/fphar.2023.1046514","article-title":"Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice","volume":"14","author":"Peng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"111686","DOI":"10.1016\/j.intimp.2024.111686","article-title":"Synergistic effects of tetramethylpyrazine and astragaloside IV on spinal cord injury via alteration of astrocyte A1\/A2 polarization through the Sirt1-NF-\u03baB pathway","volume":"131","author":"Rao","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1021\/jm501981g","article-title":"Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications","volume":"58","author":"Ruiz","year":"2015","journal-title":"J. Med. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","article-title":"Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine","volume":"16","author":"Serrano","year":"2024","journal-title":"Pharmaceutics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ipha.2024.03.001","article-title":"Computational transformation in drug discovery: a comprehensive study on molecular docking and quantitative structure activity relationship (QSAR)","volume":"2","author":"Shah","year":"2024","journal-title":"Intell. Pharm."},{"key":"B70","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0893-133x(00)00252-9","article-title":"Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve","volume":"25","author":"Sora","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cpt197824152","article-title":"Kinetics of intravenous and intramuscular morphine","volume":"24","author":"Stanski","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.toxlet.2006.05.007","article-title":"Toxicological analysis in rats subjected to heroin and morphine overdose","volume":"166","author":"Strandberg","year":"2006","journal-title":"Toxicol. Lett."},{"key":"B74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.taap.2014.05.005","article-title":"Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats","volume":"279","author":"Sun","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"886","DOI":"10.16438\/j.0513-4870.1986.12.002","article-title":"Studies on the analgesic action and physical dependence of bulleyaconitine A","volume":"21","author":"Tang","year":"1986","journal-title":"Acta Pharm. Sin."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/neu.20079","article-title":"Thermosensation and pain","volume":"61","author":"Tominaga","year":"2004","journal-title":"J. Neurobiology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1336025","DOI":"10.3389\/fddsv.2024.1336025","article-title":"Machine learning in toxicological sciences: opportunities for assessing drug toxicity","volume":"4","author":"Tonoyan","year":"2024","journal-title":"Front. Drug Discov."},{"key":"B78","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nature01786","article-title":"P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury","volume":"424","author":"Tsuda","year":"2003","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.compbiolchem.2007.10.003","article-title":"Aconitum and delphinium sp. alkaloids as antagonist modulators of voltage-gated Na+ channels: AM1\/DFT electronic structure investigations and QSAR studies","volume":"32","author":"Turabekova","year":"2008","journal-title":"Comput. Biology Chemistry"},{"key":"B80","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","article-title":"Opioid receptors","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1055\/s-2007-971658","article-title":"Alkaloids from roots of aconitum crassicaule.pdf","volume":"42","author":"Wang","year":"1981","journal-title":"J. Med. Plant Res."},{"key":"B82","volume-title":"Study on the structural modification of analgesics lappaconitine and bulleyaconitine and the oxidation of aliphatic cyclic ether to lactone","author":"Wang","year":"2004"},{"key":"B83","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/01.anes.0000267502.18605.ad","article-title":"Bulleyaconitine A isolated from aconitum plant displays long-acting local anesthetic properties in vitro and in vivo","volume":"107","author":"Wang","year":"2007","journal-title":"Anesthesiology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1213\/ane.0b013e318182401b","article-title":"Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat","volume":"107","author":"Wang","year":"2008","journal-title":"Anesth. & Analgesia"},{"key":"B85","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1248\/cpb.57.801","article-title":"Structure\u2013analgesic activity relationship studies on the C18-and C19-diterpenoid alkaloids","volume":"57","author":"Wang","year":"2009","journal-title":"Chem. Pharm. Bull."},{"key":"B86","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1039\/b916679c","article-title":"Diterpenoid alkaloids","volume":"27","author":"Wang","year":"2010","journal-title":"Nat. Product. Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"124414","DOI":"10.1016\/j.ijpharm.2024.124414","article-title":"Long-acting bulleyaconitine A microspheres via intra-articular delivery for multidimensional therapy of rheumatoid arthritis","volume":"661","author":"Wang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3969\/j.issn.1006-6233.2020.11.02","article-title":"Mechanisms of bulleyaconitine A relieving pain in rats with neuropathic pain by regulating TRPV1 receptor function","volume":"26","author":"Wei","year":"2020","journal-title":"HeBei Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1248\/bpb.28.747","article-title":"A pharmacokinetic study of intramuscular administration of bulleyaconitine A in healthy volunteers","volume":"28","author":"Weng","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.12998\/wjcc.v9.i9.2100","article-title":"Expert consensus of the Chinese association for the study of pain on ion channel drugs for neuropathic pain","volume":"9","author":"Xiao","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e44389","DOI":"10.1097\/MD.0000000000044389","article-title":"Efficacy and safety of bulleyaconitine A in the treatment of osteoarthritis: a systematic review and meta-analysis","volume":"104","author":"Xiao","year":"2025","journal-title":"Medicine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1744806918778491","DOI":"10.1177\/1744806918778491","article-title":"Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: the role of preferably blocking Nav1.7 and Nav1.3 channels","volume":"14","author":"Xie","year":"","journal-title":"Mol. Pain"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1744806918797243","DOI":"10.1177\/1744806918797243","article-title":"Mechanisms for therapeutic effect of bulleyaconitine A on chronic pain","volume":"14","author":"Xie","year":"","journal-title":"Mol. Pain"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1271\/bbb.90064","article-title":"Sensitive quantification of bulleyaconitine A in human serum by liquid chromatography-tandem mass spectrometry","volume":"73","author":"Xiong","year":"2009","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.7501\/j.issn.1674-5515.2023.10.043","article-title":"Research progress on analgesic mechanism of bulleyaconitine A and its treatment of pain","volume":"38","author":"Xu","year":"2023","journal-title":"Drugs & Clin."},{"key":"B96","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.brainres.2006.01.095","article-title":"Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors","volume":"1083","author":"Yamada","year":"2006","journal-title":"Brain Res."},{"key":"B97","article-title":"Research advances of bulleyaconitine A. World clinical drugs. 34 (2)","author":"Yang","year":"2013"},{"key":"B98","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/wjtcm.wjtcm_77_20","article-title":"Safety assessment of aconitum-derived bulleyaconitine A: a 91-Day oral toxicity study and a tissue accumulation study in rats","volume":"7","author":"Yin","year":"2021","journal-title":"World J. Traditional Chin. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.12659\/msm.915427","article-title":"Bulleyaconitine A effectively relieves allergic lung inflammation in a murine asthmatic model","volume":"25","author":"Zhan","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1039\/c6nr08486a","article-title":"Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks","volume":"9","author":"Zhang","year":"2017","journal-title":"Nanoscale"},{"key":"B101","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.1002\/jcp.26508","article-title":"Bulleyaconitine A prevents Ti particle-induced osteolysis via suppressing NF-\u03baB signal pathway during osteoclastogenesis and osteoblastogenesis","volume":"233","author":"Zhang","year":"2018","journal-title":"J. Cell Physiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"21211","DOI":"10.1021\/acsomega.0c02944","article-title":"Synthesis and evaluation of a series of new bulleyaconitine A derivatives as analgesics","volume":"5","author":"Zhang","year":"2020","journal-title":"ACS Omega"},{"key":"B103","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/toxics13070525","article-title":"Artificial intelligence-driven drug toxicity prediction: advances, challenges, and future directions","volume":"13","author":"Zhang","year":"2025","journal-title":"Toxics"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1339364","DOI":"10.3389\/fchem.2024.1339364","article-title":"Aconitine and its derivatives: bioactivities, structure-activity relationships and preliminary molecular mechanisms","volume":"12","author":"Zhao","year":"2024","journal-title":"Front. Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.expneurol.2015.09.006","article-title":"Bulleyaconitine A depresses neuropathic pain and potentiation at C-fiber synapses in spinal dorsal horn induced by paclitaxel in rats","volume":"273","author":"Zhu","year":"2015","journal-title":"Exp. Neurol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1733973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:55:11Z","timestamp":1771916111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1733973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":106,"alternative-id":["10.3389\/fphar.2025.1733973"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1733973","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"1733973"}}